Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura. (15th October 2020)

• Record Type: Journal Article
• Authors: Sakai, Kazuya; Fujimura, Yoshihiro; Nagata, Yasuyuki; Higasa, Satoshi; Moriyama, Masato; Isonishi, Ayami; Konno, Mutsuko; Kajiwara, Michiko; Ogawa, Yoshiyuki; Kaburagi, Shigehiko; Hara, Tomoko; Kokame, Koichi; Miyata, Toshiyuki; Hatakeyama, Kinta; Matsumoto, Masanori
• Is Part Of: Journal of thrombosis and haemostasis. Volume 18:Number 11(2020)
• Page Start: 2929
• Page End: 2941
• Publication Date: 2020-10-15
• Subjects: ADAMTS13 protein -- fresh frozen plasma -- pregnancy complications -- thrombotic thrombocytopenic purpura -- Upshaw‐Schulman syndrome; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.15064
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract: Background: Congenital thrombotic thrombocytopenic purpura (cTTP), otherwise known as Upshaw‐Schulman syndrome, is an extremely rare hereditary disease. Pregnancy is identified as a trigger for TTP episodes in patients with cTTP. Objectives: To investigate the ideal management of pregnant patients with cTTP. Patients/Methods: We identified 21 patients with a reproductive history (38 pregnancies) in a Japanese cTTP registry. Fetal outcomes were compared between two groups: group 1 (n = 12), pregnancy after diagnosis of confirmed cTTP by ADAMTS13 gene analysis; and group 2 (n = 26), pregnancy before diagnosis of confirmed cTTP. Results: In group 1, ADAMTS13 activity was closely monitored until delivery in most cases. Among 10 pregnancies in group 1, prophylactic fresh frozen plasma (FFP) infusions during pregnancy were performed to replenish ADAMTS13. In group 2, prophylactic FFP infusions were not administrated in 23 pregnancies and FFP test infusions were performed in only three pregnancies. The live birth rate of group 1 was significantly higher than that of group 2 (91.7% vs 50.0%, respectively, P = .027). The fetal survival rates of women without FFP infusions were dramatically decreased after 20 weeks of gestation. The FFP infusion dosage in group 1 was generally higher than 5 mL/kg/wk by 20 weeks of gestation. Conclusions: Our results indicate that FFP infusions of more than 5 mL/kg/wk should be initiated as soon as patients become pregnant. However, even with these infusions, patients with repeated TTP episodes before pregnancy might have difficulty giving birth successfully. Recombinant ADAMTS13 products might be new treatment options for pregnant patients with cTTP.